The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Gabriella Ferrandina

Gynecologic Oncology Unit

Catholic University

Italy

[email]@libero.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Gynecologic Oncology Unit, Catholic University, Italy. 2012
  • Department of Oncology, Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Campobasso, Italy. 2012
  • Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy. 2004 - 2012
  • Catholic University of the Sacred Heart, Gynecologic Oncology Unit, Department of Oncology, Campobasso. 2009 - 2012

References

  1. Malignant transformation of Madelung's disease in a patient with a coincidental diagnosis of breast cancer: a case report. Borriello, M., Lucidi, A., Carbone, A., Iannone, V., Ferrandina, G. Diagn. Pathol (2012) [Pubmed]
  2. Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects. Petrillo, M., Borriello, M., Fuoco, G., Legge, F., Iannone, V., Ferrandina, G. Curr. Pharm. Des. (2012) [Pubmed]
  3. Can radicality of surgery be safely modulated on the basis of MRI and PET/CT imaging in locally advanced cervical cancer patients administered preoperative treatment? Ferrandina, G., Petrillo, M., Restaino, G., Rufini, V., Macchia, G., Carbone, A., Zannoni, G.F., Lucidi, A., D'Angelo, G., Scambia, G. Cancer (2012) [Pubmed]
  4. Novel targets for VEGF-independent anti-angiogenic drugs. Petrillo, M., Scambia, G., Ferrandina, G. Expert. Opin. Investig. Drugs (2012) [Pubmed]
  5. Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. Legge, F., Paglia, A., D'Asta, M., Fuoco, G., Scambia, G., Ferrandina, G. BMC. Cancer (2011) [Pubmed]
  6. Pegylated liposomal doxorubicin in the management of ovarian cancer. Ferrandina, G., Corrado, G., Licameli, A., Lorusso, D., Fuoco, G., Pisconti, S., Scambia, G. Ther. Clin. Risk. Manag (2010) [Pubmed]
  7. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Ferrandina, G., Mey, V., Nannizzi, S., Ricciardi, S., Petrillo, M., Ferlini, C., Danesi, R., Scambia, G., Del Tacca, M. Cancer Chemother. Pharmacol. (2010) [Pubmed]
  8. Hospital costs incurred by the Italian National Health Service for invasive cervical cancer. Ferrandina, G., Marcellusi, A., Mennini, F.S., Petrillo, M., Di Falco, C., Scambia, G. Gynecol. Oncol. (2010) [Pubmed]
  9. CD133 antigen expression in ovarian cancer. Ferrandina, G., Martinelli, E., Petrillo, M., Prisco, M.G., Zannoni, G., Sioletic, S., Scambia, G. BMC. Cancer (2009) [Pubmed]
  10. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Ferrandina, G., Sallustio, G., Fagotti, A., Vizzielli, G., Paglia, A., Cucci, E., Margariti, A., Aquilani, L., Garganese, G., Scambia, G. Br. J. Cancer (2009) [Pubmed]
  11. Targeting CD133 antigen in cancer. Ferrandina, G., Petrillo, M., Bonanno, G., Scambia, G. Expert Opin. Ther. Targets (2009) [Pubmed]
  12. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Ferrandina, G., Ludovisi, M., Corrado, G., Carone, V., Petrillo, M., Scambia, G. Gynecol. Oncol. (2008) [Pubmed]
  13. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., Del Medico, P., Scaltriti, L., Katsaros, D., Priolo, D., Scambia, G. J. Clin. Oncol. (2008) [Pubmed]
  14. Expression of CD133-1 and CD133-2 in ovarian cancer. Ferrandina, G., Bonanno, G., Pierelli, L., Perillo, A., Procoli, A., Mariotti, A., Corallo, M., Martinelli, E., Rutella, S., Paglia, A., Zannoni, G., Mancuso, S., Scambia, G. Int. J. Gynecol. Cancer (2008) [Pubmed]
  15. Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?. Ferrandina, G., Fanfani, F., Ludovisi, M., Fagotti, A., Carbone, A., Zannoni, G., Guerriero, M., Petrillo, M., Scambia, G. Gynecol. Oncol. (2008) [Pubmed]
  16. A case of isolated ovarian recurrence from vulvar carcinoma. Ferrandina, G., Petrillo, M., Zannoni, G.F., Testa, A., Sioletic, S., Scambia, G. Arch. Gynecol. Obstet. (2008) [Pubmed]
  17. Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients. Ferrandina, G., Petrillo, M., Carbone, A., Zannoni, G., Martinelli, E., Prisco, M., Pignata, S., Breda, E., Savarese, A., Scambia, G. Br. J. Cancer (2008) [Pubmed]
  18. Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Ferrandina, G., Macchia, G., Legge, F., Deodato, F., Forni, F., Digesù, C., Carone, V., Morganti, A.G., Scambia, G. Oncology (2008) [Pubmed]
  19. Conservatively treated glassy cell carcinoma of the cervix. Ferrandina, G., Salutari, V., Petrillo, M., Carbone, A., Scambia, G. World. J. Surg. Oncol (2008) [Pubmed]
  20. Lymph node involvement in locally advanced cervical cancer patients administered preoperative chemoradiation versus chemotherapy. Ferrandina, G., Distefano, M., Ludovisi, M., Morganti, A., Smaniotto, D., D'Agostino, G., Fanfani, F., Scambia, G. Ann. Surg. Oncol. (2007) [Pubmed]
  21. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ferrandina, G., Ludovisi, M., De Vincenzo, R., Salutari, V., Lorusso, D., Colangelo, M., Prantera, T., Valerio, M.R., Scambia, G. Ann. Oncol. (2007) [Pubmed]
  22. Glassy cell carcinoma of the endometrium: a case report and review of the literature. Ferrandina, G., Zannoni, G.F., Petrillo, M., Vellone, V., Martinelli, E., Scambia, G. Pathol. Res. Pract. (2007) [Pubmed]
  23. A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge. Ferrandina, G., Legge, F., Mey, V., Nannizzi, S., Ricciardi, S., Petrillo, M., Corrado, G., Scambia, G. Cancer Chemother. Pharmacol. (2007) [Pubmed]
  24. Endometrial carcinoma recurring as carcinosarcoma: report of two cases. Ferrandina, G., Zannoni, G.F., Martinelli, E., Vellone, V., Prisco, M.G., Scambia, G. Pathol. Res. Pract. (2007) [Pubmed]
  25. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. Ferrandina, G., Martinelli, E., Zannoni, G.F., Distefano, M., Paglia, A., Ferlini, C., Scambia, G. Gynecol. Oncol. (2007) [Pubmed]
  26. Serous ovarian carcinoma recurring as a heterologous carcinosarcoma. Ferrandina, G., Carbone, A., Zannoni, G.F., Martinelli, E., Testa, A.C., Gallotta, V., De Ninno, M., Scambia, G. J. Obstet. Gynaecol. Res. (2007) [Pubmed]
  27. Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer. Ferrandina, G., Ranelletti, F.O., Legge, F., Salutari, V., Martinelli, E., Fattorossi, A., Lorusso, D., Zannoni, G., Vellone, V., Paglia, A., Scambia, G. Clin. Cancer Res. (2006) [Pubmed]
  28. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Ferrandina, G., Zannoni, G.F., Martinelli, E., Paglia, A., Gallotta, V., Mozzetti, S., Scambia, G., Ferlini, C. Clin. Cancer Res. (2006) [Pubmed]
  29. Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Ferrandina, G., Distefano, M., Smaniotto, D., Morganti, A., Paglia, A., Macchia, G., Corvari, B., Lorusso, D., Scambia, G. Gynecol. Oncol. (2006) [Pubmed]
  30. Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature. Ferrandina, G., Salutari, V., Testa, A., Zannoni, G.F., Petrillo, M., Scambia, G. BMC. Cancer (2006) [Pubmed]
  31. Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. Ferrandina, G., Ranelletti, F.O., Martinelli, E., Paglia, A., Zannoni, G.F., Scambia, G. BMC. Cancer (2006) [Pubmed]
  32. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Ferrandina, G., Legge, F., Salutari, V., Paglia, A., Testa, A., Scambia, G. Eur. J. Cancer (2006) [Pubmed]
  33. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Ferrandina, G., Legge, F., Martinelli, E., Ranelletti, F.O., Zannoni, G.F., Lauriola, L., Gessi, M., Gallotta, V., Scambia, G. Br. J. Cancer (2005) [Pubmed]
  34. Skull metastasis in primary vulvar adenocarcinoma of the Bartholin's gland: a case report. Ferrandina, G., Testa, A.C., Zannoni, G.F., Poerio, A., Scambia, G. Gynecol. Oncol. (2005) [Pubmed]
  35. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Ferrandina, G., Paris, I., Ludovisi, M., D'Agostino, G., Testa, A., Lorusso, D., Zanghi, M., Pisconti, S., Pezzella, G., Adamo, V., Breda, E., Scambia, G. Gynecol. Oncol. (2005) [Pubmed]
  36. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Ferrandina, G., Ranelletti, F.O., Gallotta, V., Martinelli, E., Zannoni, G.F., Gessi, M., Scambia, G. Gynecol. Oncol. (2005) [Pubmed]
  37. Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report. Ferrandina, G., Zannoni, G.F., Gallotta, V., Foti, E., Mancuso, S., Scambia, G. Gynecol. Oncol. (2005) [Pubmed]
  38. Cyclooxygenase-2 expression in borderline ovarian tumors. Ferrandina, G., Zannoni, G.F., Ranelletti, F.O., Legge, F., Gessi, M., Salutari, V., Gallotta, V., Lauriola, L., Scambia, G. Gynecol. Oncol. (2004) [Pubmed]
 
WikiGenes - Universities